Article

PDF
Access to the PDF text
Advertising



Archives of cardiovascular diseases
Volume 103, n° 8-9
pages 469-476 (août 2010)
Doi : 10.1016/j.acvd.2010.04.006
Received : 1 February 2010 ;  accepted : 2 April 2010
Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure
Thérapie génique pour l’ischémie myocardique et la dysfunction ventriculaire gauche systolique ou l’insuffisance cardiaque
 

Figure 1




Figure 1 : 

Combining gene therapies with an IRES-based system. With standard nonviral vectors, therapy that combines two genes (top and middle) requires the administration of two independent plasmids; however, the genes may not be expressed in the intended ratio, because one of the vectors could be preferentially silenced or removed. In an IRES-based system (bottom), a single vector can encode two (or more) genes separated by an IRES, thereby maintaining the intended expression ratio and decreasing the risk of adverse effects associated with the administration of several vectors. Collectively, these effects could substantially improve the risk-to-benefit ratio, which is of primary importance for potential clinical applications. IRES: internal ribosome entry site; pCMV: cytomegalovirus promoter.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline